Monthly Archives: August 2020

Every Superman Movie Climax, Ranked From Worst To Best – Screen Rant

Posted on by

After debuting in the pages of the comic books nearly a century ago, Superman has been perhaps the most iconic superhero of all time. With that level of popularity, of course, came movies, with the classic films starring Christopher Reeve right up to the more recent films in the DCEU.

RELATED:The 10 Best Superman Movies, According To IMDb

There is a thrill to seeing a hero like Superman take on the bad guys and save the day. The climaxes of these live-action films have thrilled audiences of all ages while some of them have maybe been a bit disappointing. Looking back on each of the live-action films featuring Superman, here are the climaxes ranked from worst to best.

Superman III is often criticized for being too cartoonish and filled with slapstick humor. When looking at the film's climax, it's hard to argue with that criticism. As an evil corporate villain is trying to use a super-computer to carry out disasters around the world that will benefit him financially, Superman flies in to save the day.

RELATED:You'll Believe A Man Can Fly: 10 Behind-The-Scenes Facts About Superman (1978)

The sequence is filled with ridiculous moments, like the villain playing a video game that fires rockets at Superman. There is also a moment when the computer inexplicably turns one of the villains into a cyborg which Superman then has to fight. It was a strange way to end an already strange movie.

Christopher Reeve gives his final performance as Superman in this fourth adventure. After giving such an iconic performance in the role, it's a shamehe didn't have a better movie to end on.

Superman IV: The Quest For Peace centers around Superman's attempts to rid the world of nuclear weapons, but Lex Luthor succeeds in creating a new villain named Nuclear Man. The movie is little more than Superman and Nuclear Man chasing each other around the world and getting into dull fights. Even when they take their battle to the moon, it's not very exciting, largely due to the boring villain.

Fans had been waiting for years to see the Justice League team up in a live-action film. Though Justice League has some fun moments in it, the fact that it is overall a rather forgettable film is a massive disappointment for the DCEU.

Even the climactic battle against the villainous Steppenwolf fails to deliver much fun. There are some good character moments and action sequences, and the return of Superman is pretty thrilling. But once Superman shows up, the fight is pretty much over and it makes you wonder why the team was even necessary in the first place.

The long-awaited face-off between Batman and Superman was another big letdown for the DCEU, with many fans put off by the dark and over-plotted story. However, the movie did deliver some exciting action, including the fight between the two heroes and Batman's raid of a criminal warehouse.

RELATED:Batman V Superman: 10 Interesting Behind-The-Scenes Details

The climactic battle against Doomsday is, sadly, not as thrilling as those other sequences. There is some fun seeing Batman, Superman, and Wonder Woman team up, withWonder Woman easily stealing the show. But the last-minute addition of Doomsday feels tacked on as does Superman's death at the end of the fight.

After a long hiatus from any big-screen adventures, Superman Returns sought to, well, return the character to his heroic roots in the continuation of the original Richard Donner films. Some fans found this new entrytoo reliant on nostalgia, but it does effectively show Superman at his most heroic.

After Lex Luthor creates a new island made out of Kryptonite, Superman is weakened. But with the new expanding land threatening others, Superman uses all of his strength to fly the island into space before crashing back down to Earth. It is a moment that reminds everyone of the kind of hero Superman is one who will do whatever it takes to save the day.

Though not all of the Christopher Reeve's sequels were successful, Superman II is considered by many to be an equal or possibly greater film than the original. The film sees Superman meet his match as three Kryptonian criminals, led by General Zod, arrive on Earth, and challenge the son of Jor-El.

After losing his power for a short time, Superman returns, ready to take on the challengers. The exciting fight begins in the skies over Metropolis before heading to the Fortress of Solitude. Though the action might not be as fast-paced as modern superhero movies, it's a fun and clever battle with villains who are Superman's equals.

Superman took on Zod once again in Zack Snyder's Man of Steel. Zod comes to Earth seeking out Superman as an ally. Hehopes to transform the planet into a new Kryptonian home, but it means the death of the human race. Obviously, Superman will not stand for that.

RELATED:10 Actors Who Were Almost Cast As Superman Villains

The massive destruction of the battle drew criticism, but it feels like it carries consequences in the later films. Snyder does shape some pretty thrilling fight sequences and the moment when Superman is forced to kill Zod, while controversial, was as an interesting new path to take the iconic hero.

While there are plenty of fans of Snyder's version of Superman, many feel that this darker version of was missing the fundamental hero component of his character. It is not just that he is a godlike being, he is capable of saving lives and is a beacon of good around the world.

The original Superman movie really embraced this aspect of the character, especially in the climax. After Luthor generates an earthquake that threatens the entire West Coast, Superman flies around saving school buses from bridges and trains filled with passengers. And when he finds the quake killed Lois Lane, he flies around the world as fast as he can and reverses time to save her. It's ridiculous, but it's the kind of feel-good heroics the character has always embodied.

NEXT:Superman: 10 Best TV & Film Costumes, Ranked

Next The Simpsons: 10 Funniest Bart Simpson Memes That Make Us Laugh

A writer and film fan. I always enjoy keeping up with the latest films in theaters as well as discovering some hidden gems I may have overlooked. Glad to be a part of Screen Rant's positive and fun community and have the opportunity to share my thoughts with you.

More here:

Every Superman Movie Climax, Ranked From Worst To Best - Screen Rant

Public apathy is the most powerful enemy of tech regulation – NS Tech

Posted on by

Four years ago, Trump was elected under a fog of accusations and outrage. In November, itll be time to do it all again. His 2016 march on the White House left commentators wondering: if Barack Obama had been the first to really leverage the promise of technology in political campaigning, perhaps Trump was the first to wield its dark side.

Committees in the Commons and the Lords and the Electoral and Information Commissioners have in the past year or so raised the alarm, not to mention voices in the media, in civil society and even in technology itself. Our electoral laws are not fit for purpose.

The ability of Big Tech to understand and sculpt political messaging for the electorate and crucially to be able to communicate with specific groups of voters with specially crafted advertisements, which are not accessible by other voters who may be put off by the same messages is an unprecedented and dangerous power. And yet it is currently subject to far lighter regulation than traditional campaigning mediums like television ads and leaflets, our laws left un-updated from a time when the use and misuse of digital campaigning was in the realm of science fiction, not established fact.

We are at the mercy of the platforms. That Big Tech now plays a pivotal role in our democracies is lost on few, and for the most part, we seem to be ready for change. Whether they are headlines about Russian interference, or whispers about the dangers of Big Data and profiling, the power of technology to shape our politics is now a mainstream worry: the public overwhelmingly back greater regulation of the role of Big Tech in politics. Eight in ten now favour campaigns having to openly publish all advertising materials used and how much they are spending in digital campaigning.

Eight in ten, but not everyone.

The shape of regulation, and who should be leading the way, remain topics of division. And it seems the fight to convince sceptics is against public apathy and nihilism, rather than principles of free speech or faith in democracy.

Thats the key finding of a new report from Demos and the Open Rights Group exploring public attitudes around data driven political campaigning. We used Polis, an open-source tool which allows participants to submit their views in their own words, and to vote as to whether they agree or disagree with each others statements with this project pioneering the use of the tool with a nationally representative sample for the first time. It also maps out how opinions interact, and how different groups of views hang together.

Who, then, is not on board with regulation? Just over half of people think there should be less red tape stopping politicians saying and doing what their voters want, and say authorities shouldnt control what politicians are allowed to say.

But there is more to it than just an irritation with bureaucracy. This group of regulation sceptics, who over-indexed among working class Britons and Leave voters, were remarkably in favour of abolishing political campaigning altogether. More than two thirds of the group agreed to the following statements, submitted by their peers:

Doing this would likely mean more regulation, not less, but it would be wrong to discount this simply as a contradiction. The voices of these regulation-doubters help us understand where they are coming from.

The anti-regulation group were most likely to be distrustful of both politicians and regulators alike. They want change, but dont trust the powers that be with making it happen. The vast majority agreed with the statements I dont trust any of the politicians or their departments to keep my data safe, nor use it for the right purposes and I dont trust the people who regulate campaigns to be unbiased.

They were also the most convinced that political campaigns have no impact on their voting behaviour, with around seven in ten agreeing with each of the following again all submitted by participants:

In other words, regulation of data driven political campaigns is unnecessary bureaucracy itself. Instead, lets abolish political campaigning wholesale. This is anti-regulation not on grounds of freedom of speech or faith in the political system, but through a strong feeling of being fed up. Fed up with the political sphere, fed up with regulators, and fed up with the media.

To win the argument for regulation, sceptics must be convinced of the dangerous power of data driven political campaigning. Most opponents of regulation are convinced that politicians and Big Tech are not to be trusted but they also think the same is true for regulators, and that none of it really matters anyway. The challenge is to persuade them that it does matter that the power of Big Tech represents a far graver threat to democracy than the untrustworthy politicians that have always been fixtures of our lives and to distinguish between political actors and those looking to hold them to account.

Many of the issues around regulating Big Tech are extremely difficult to legislate for, and require radical new ideas to deal with unprecedented new problems. Regulation of data driven political campaigning is not one of them. The same principles as have governed political campaigning for decades can be updated to apply to the modern world: records of online political adverts should be collated and published for everyone to see; political campaigns should have to report how much they are spending using digital advertising, what they are spending it on, and how they are funded; and those who break electoral laws should face harsher penalties rather than a slap on the wrist. The vast majority of the public support each of those changes. An issue will be that whoever has just won an election may feel they have an advantage of the way the system currently works.

November is coming. As we look across the pond, we might allow ourselves a little hope as Biden leads Trump in poll after poll. But lets not get too excited. There are plenty of voters who are still fed up, still sceptical that this political system offers them anything. That same feeling that many realised (too late) was behind Trumps election, that many blamed (too late!) for the Brexit vote, is still alive and well. Many politicians have found success in promising to reinvigorate their democracies: to take back control, to drain the swamp, to get back to the things that matter. If our findings are anything to go by, many of those for whom this sounded like the change they wanted remain outside our democratic fold.

Harry Carr is director of innovation at Demos

More:

Public apathy is the most powerful enemy of tech regulation - NS Tech

Charen: Who Is really burning things down? | National Commentary – Standard-Examiner

Posted on by

My friend David French, one of the most admirable voices in America today, argues that conservatives need not vote against Republican senate candidates in order to send a message about Trumpism. I disagree. He writes, A rage, fury, and a burn it all down mentality is one of the maladies that brought us to the present moment.

This assumes that the reason some plan to evict Republican senators is simply a matter of anger. But voting against a candidate or even a whole party is not nihilism. Its the legal, Constitutional way to express approval or disapproval. The current Republican Party has chosen to become the burn-it-all-down party. The most demoralizing aspect of the past four years has not been that a boob conman was elected president but that one of the two great political parties surrendered to him utterly.

David suggests that voting against Republican senators ignores that they had bad choices.

Its certainly true that Republicans perceived their options to be limited. If they speak up, they say, they will flush their careers down the drain. Look at what happened to Jeff Flake, Mark Sanford and Bob Corker!

But this overstates things. A number of Republicans have stood up to Trump and maintained their electoral viability especially when they challenged him on matters in which he has shown little interest, namely public policy. Sen. Pat Toomey, R-Pa., for example, voted against the presidents USMCA trade agreement and (gasp) wrote an op-ed in The Wall Street Journal explaining his reasoning.

When the president abruptly announced, following a phone call with Turkish leader Recep Erdogan, that he was withdrawing American troops forthwith from Syria, a number of Republicans voiced horror. Sen. Ben Sasse, R-Neb., said it would lead to a slaughter. Sen. Ted Cruz said it would be DISGRACEFUL. Rep. Liz Cheney called it a catastrophic mistake that puts our gains against ISIS at risk and threatens Americas national security. Senators Lindsay Graham, R-S.C., Mitch McConnell, R-Ky., Mitt Romney, R-Utah, Marco Rubio, R-Fla., former U.N. Ambassador Nikki Haley and others weighed in as well.

When the president suggested lifting sanctions on Russia, Senator Rob Portman, R-Ohio, said it would be horrible for the United States. And after Gen. James Mattis wrote an op-ed saying that Donald Trump was making a mockery of the U.S. Constitution, Sen. Lisa Murkowski said: I was really thankful. I thought General Mattis words were true, and honest and necessary and overdue.

So, it is possible to speak up about this president and survive. I use that word advisedly, because these Republican officeholders often use words like kill or destroy or annihilate when contemplating what Trump would do to them if they raise their heads too far above the parapet. In fact, all that actually threatened them was the possibility of nasty tweets and the chance that they might lose their seats.

David is right that very few people in any walk of life display courage on anything, though craven Republicans holding House and Senate posts might want to pause from time to time to contemplate the extraordinary valor of protesters in Hong Kong, Iran and Egypt who continue to put their freedom and sometimes their lives at risk by taking to the streets. And should being an elected official really be ones life work?

As noted above, Republicans have criticized the president on policy matters, sometimes even harshly. Where they have shrunk into their shells was on matters that are even more critical to the health of our republic. They have, by their silence, given assent to his cruelty, his assaults on truth, his dangerous flirtations with political violence and his consistent demolition of institutions.

Institutions are like scaffolding. When a societys institutions are weakened, the whole edifice can come crashing down.

Donald Trump undermined the institution of the free press, urging his followers to disbelieve everything except what came from the leader. He weakened respect for law enforcement and the courts, suggesting that he was the victim of a deep state and that so-called judges need not be respected. He scorned allies and toadied to dictators. He has cast doubt on the integrity of elections. He ran the executive branch like a gangster, demanding personal loyalty and abusing officials such as the hapless Jeff Sessions, who merely followed ethics rules. He ignored the law to get his way on the border wall. He violated the most sacred norms of a multiethnic society by encouraging racial hatred. He made the U.S. guilty of separating babies from their mothers.

Elected officials, terrified of their own constituents, have cowered and temporized in the face of a truly unprecedented assault on democratic values. They believed that they were powerless and acted accordingly. Since they were powerless when it counted, perhaps we should make it official?

Mona Charen is a senior fellow at the Ethics and Public Policy Center. Her new book is Sex Matters: How Modern Feminism Lost Touch with Science, Love, and Common Sense.

Original post:

Charen: Who Is really burning things down? | National Commentary - Standard-Examiner

Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 – PRNewswire

Posted on by

FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ --Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK) cells (CYNK-001) for the treatment of adults with COVID-19.The University of California Irvine is the first CA site to open for patient enrollment.

CIRM's COVID-19 Project supports promising discovery, preclinical and clinical trial stage projects that could quickly advance treatments or vaccines that utilize stem and/or progenitor cells. Celularity will use the CIRM grant to support the evaluation of the anti-viral activities of its cryopreserved investigational product, CYNK-001, in underserved and disproportionately affected populations with COVID-19, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Celularity received clearance from the United States Food and Drug Administration to proceed with a Phase I/II study to evaluate the safety, tolerability, and efficacy of CYNK-001 in patients with COVID-19.

"Our investigational product CYNK-001 showed great promise in preclinical studies, and we are optimistic that it will prove effective against corona virus diseases, including COVID-19. As part of our rapidly-scalable placental-derived cellular medicine platform, CYNK-001 could play an important role in the public health response to outbreaks of COVID-19 or other coronaviruses," said Robert J. Hariri, MD, PhD, Founder, Chairman and CEO of Celularity. "We are very grateful to CIRM for supporting our effort to make novel cellular medicines available to medically underserved and disproportionately affected persons in California."

Xiaokui Zhang, PhD, Chief Scientific Officer and Principal Investigator under the CIRM grant says "CYNK-001 has a range of biological activities that not only recognize and destroy virus-infected cells, but also coordinate a robust immune response that may lead to an effective and durable defense against the viral infection."

The trial will evaluate the safety and the clinical efficacy of CYNK-001 in SARS-CoV-2 positive subjects as measured by clearance of the SARS-CoV-2 and improvement in clinical symptoms or improvement in radiological evaluation of disease related chest x-ray. The primary objective of the Phase I portion of the study is to evaluate the safety, tolerability, and efficacy of multiple CYNK-001 intravenous (IV) infusions in COVID-19 patients and will be administered to up to 14 patients in three doses over the course of seven days.

The Phase II portion of the study is a randomized, open-label, multi-site study measuring multiple doses of CYNK-001 against a control group experiencing a similar degree of infection with best supportive care, with two co-primary endpoints. The first co-primary endpoint is to determine the virologic efficacy of CYNK-001 in facilitating the clearance of SARS-CoV-2 from mucosal specimens and/or peripheral blood. The second co-primary endpoint is to assess the impact of treatment with CYNK-001 on clinical symptoms among patients with COVID-19 related lower respiratory tract infection.

Celularity has treated patients with severe COVID-19 and on ventilator support under compassionate use programs in U.S. CYNK-001 was well tolerated and may be associated with clinical benefit in selected cases.

About NK CellsNK cells are innate immune cells with an important role in early host response against various pathogens. Multiple NK cell receptors are involved in the recognition of infected cells. Studies in humans and mice have established that there is robust activation of NK cells during viral infection, regardless of the virus class, and that the depletion of NK cells aggravates viral pathogenesis.

About CYNK-001CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy developed from placental hematopoietic stem cells. CYNK-001 is being investigated as a potential treatment option in adults with COVID-19, as well as for various hematologic cancers and solid tumors. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity. CYNK-001 cells derived from the placenta are currently being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and glioblastoma multiforme (GBM). On 1 April, the U.S. Food and Drug Administration cleared the Company's Investigational New Drug (IND) application for the use of CYNK-001 in adults with COVID-19.

About COVID-19The virus causing COVID-19 is called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is a novel coronavirus that has not been previously identified. COVID-19 has become a global pandemic, with over 4.2 million confirmed cases in the USA and over 650,000 deaths reported to date worldwide.

About CelularityCelularity, headquartered in Florham Park, N.J., is a next-generation Biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics. Celularity's innovative approach to cell therapy harnesses the unique therapeutic potential locked within the cells of the post partum placenta. Through nature's immunotherapy engine the placenta Celularity is leading the next evolution of cellular medicine with placental-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com

Media Contact:

Name:Dani Frank

Email:[emailprotected]

SOURCE Celularity

Home

Excerpt from:

Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 - PRNewswire

Tafasitamab Combination Approved for Adults With R/R DLBCL – AJMC.com Managed Markets Network

Posted on by

On July 31, FDA approved tafasitamab-cxix to be used in combination with lenalidomide for second-line treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), meeting the needs of patients who are not eligible for an autologous stem cell transplant.

Tafasitamab, to be sold as Monjuvi by MorphoSys and Incyte, is a humanized Fc-modified cytolytic CD19 monoclonal antibody being studied in several B-cell malignancies. As described in the journal Blood, the treatment uses Xencors proprietary Xmab technology, which deploys a different technique to boost affinity for the antigen and make various receptors especially capable of binding to it. In 2018, authors in Annals of Oncology described how this sets off particularly effective processes that target cancer cells and regulate cell death.

Approval was based on phase 2 results for 80 patients in the L-MIND trial, which reported an update May 2019 at the American Society of Clinical Oncology, with final results published last month in The Lancet. Results submitted to FDA showed an overall response rate of 55%, including a compete response rate of 37% and a partial response rate of 18%. Median duration of response was 21.7 months. Common adverse events included neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, and decreased appetite.

Among non-Hodgkin lymphomas, DLBCL is the most common subtype, accounting for 22% of cases in the United States and 40% worldwide, with about 18,000 US cases per year. People are at higher risk if they have HIV, an autoimmune disease, or if they have had an organ transplant. More common in older people, DLBCL can be very aggressive. Although well-known treatments have been developed, there are gapsand a notable one is when DLBCL cannot be kept in remission after chemotherapy but the patient is not eligible for an autologous stem cell transplant. Some of these patients have had chimeric antigen receptor (CAR) T-cell therapy, but this process is costly with significant side effects.

The FDA approval of Monjuvi in combination with lenalidomide helps address an urgent unmet medical need for patients with relapsed or refractory DLBCL in the United States, Herv Hoppenot, CEO of Incyte, said in a statement. At Incyte we are committed to advancing patient care and are proud to bring this new and much-needed targeted therapeutic option to appropriate patients and the clinical community.

FDA had previously granted the combination Fast Track and Breakthrough Therapy Designation in this indication.

Read more from the original source:

Tafasitamab Combination Approved for Adults With R/R DLBCL - AJMC.com Managed Markets Network

Trending News on Targeted Oncology, Week of August 7, 2020 – Targeted Oncology

Posted on by

This week in oncology news, the FDA granted approval to belantamab mafodotin-blmf (GSK2857916; Blenrep), an immunoconjugate targeted B-cell maturation antigen, for the treatment of relapsed/refractory multiple myeloma and to tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid) as treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

A Biologics License Application was also submitted to the FDA for omburtamab, which is intended for the treatment of pediatric patients with central nervous system (CNS)/leptomeningeal metastasis from neuroblastoma. A Fast Track designation was also granted to BST-236 for the treatment of older adult patients with acute myeloid leukemia. An Orphan Drug designation was also granted to SM-88 for the treatment of patients with pancreatic cancer.

FDA Approves Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma

The FDA granted approval to belantamab mafodotin-blmf for the treatment of patients with relapsed or refractory multiple myeloma who previously received treatment with at least 4 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

FDA Approves Tafasitamab/Lenalidomide for R/R DLBCL

The FDA granted approval to the combination oftafasitamab-cxix plus lenalidomide for the treatment of adultpatients with relapsed or refractory DLBCLnot otherwise specified, including DLBCL arising from low-grade lymphoma, and patients who are not eligible for autologous stem cell transplant.

Cellular Therapies Provide Hopeful Outcomes as Treatment of Patients with Myeloma

In an interview with Targeted Oncology, C. Ola Landgren, MD, PhD, discussed the development of CAR T-cell therapy in the treatment landscape of multiple myeloma.

Salvage Blinatumomab Therapy Generates Durable Responses in Relapsed/Refractory DLBCL

Salvage therapy with blinatumomab (Blincyto) may induce durable complete responses and a survival benefit as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from a pooled analysis of 3 clinical trials.

FDA Grants Orphan Drug Designation for SM-88 for Treatment of Pancreatic Cancer

The FDA has granted an Orphan Drug designation to SM-88 for the potential treatment of patients with pancreatic cancer.

Multiple Therapies Show Responses in Lung Cancer With ROS1 Fusions

Ben Levy, MD, discusses the mechanism of resistance such as the G2032R solvent front mutation in patients who received crizotinib (Xalkori) for lung cancer with ROS1 fusions and how to treat them.

Expert Perspective Tumor Board: Hepatocellular Carcinoma

In this series, Ghassan Abou-Alfa, MD, MBA, and a group of experts discuss the treatment landscape of patients with hepatocellular carcinoma in 4 separate case discussions.

Recommendations for Managing Patients With Lung Cancer During COVID-19 Era

In response to the COVID-19 pandemic, the European Society of Medical Oncology has published recommendations for the management of patients with lung cancer to maintain high-quality standards of treatment.

Follow this link:

Trending News on Targeted Oncology, Week of August 7, 2020 - Targeted Oncology

Find Out Why Bioreactor Market is thriving worldwide by top key players like mergency Response USA, Buddi US, LLC, Connect America – Owned

Posted on by

The Global Bioreactor Market Is Predicted to Reach to US$ 787.57 Mn Due to High Adoption of Bioreactor in Pharmaceutical Industries

The author of the report analyzed that the global Bioreactor market accounted for US$ 603.91 million in 2017. Bioreactor is an apparatus usually in cylindrical shape, which is used in the bioprocess technology. The vessel acts as biological catalyst which transform biowaste into biochemicals such as biofuels, biopharmaceuticals, cosmetics etc. The device is designed in such a way that it can easily process steps of segregation, purification, and handling of wastes in bioprocess technology.

Request A sample Copy of the [emailprotected]

https://www.absolutemarketsinsights.com/request_sample.php?id=102

The increasing demand towards the production facility for multi drug is driving the single use bioreactor market.The product enables the line clearence and validation of impurities in the manufacturring process of the drugs. The flexibilty provided by the product such as cost reduction, minimum production time that too without compromising the quality of the drug is further giving rise to the use of single use bioreactor in various industries such as biotech, oil and engeries, food and bevrages, etc.

Bioreactor such as fluzied bed reactor and photobioreactor both lack theavailability of sterilized sensor and has lower volume capacity. These two parameters are vital to scale up the production process and enhancement of the product quality. Hence lacking of these parameters are leading towards poor temperature control, difficult to clean, erosion of internal components etc., which ultimately increases the capital cost and limiting the progress of the bioreactor market

A large number of biopharmaceutical companies are emerging in developing countries such as India, China, Japan, Southeast Asia, Brazil and many others. Bioreactos plays an important role in tissue engenieering, cell culture, drug manufacturing and hence, increase of these application in coming future will postively impact the growth of the market.

Enquire Before [emailprotected] https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=102

Stem Cellto Remain the Dominant Application during the Forecast Period, 2018-2026

Bioreactors play an intensive role in tissue engineering. These reactors are applied for effective stem cell expansion as this cell is considered the source for various biomedical applications such as drug discovery, cell therapy and many others. Based on property of cell, bioreactor deliver suitable environment for stem cell expansion. Stirred tank bioreactor helps in uniform distribution of cells and nutrition, this equal distribution of nutrition provides adequate amount of oxygen inside the cells which help in growth of cells and maintain stem cells in normal metabolism. This further increases the clinical application of stem cells for therapeutic uses. Hence, this factor has increased the growth of bioreactor market.

North America to Remain the Dominant Region during the Forecast Period,2018-2026

The presence of a number of water management organization in this region has made it the largest market shareholder for bioreactor market. Bioreactor focuses on improving and helping the industrial water filtration process. North America has recorded 11% of worldwide installation of Bioreactor for commercial application. Due to more stringent regulations and water reuse strategies, it is expected that there will be a significant increase in bioreactor reactor market in the coming future.

Bioreactor Market isFragmented with the Presence of Global and Regional Players

Some of the key participants in global market are Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany) and GE Healthcare (U.S.), Danaher Corporation (U.S), Eppendorf AG (Germany), BBI Biotech (Germany), Biotron (Switzerland), Cellexus (UK), Fermentec (South Korea), Finesse (USA), Zenith (India). In November 2013, GE Healthcare Life Science launched a product i.e. ReadyToProcess WAVE 25 bioreactor system, this product is featured with integrated temperature sensors and load cells. These features are designed to make handling of cell cultures convenient during clinical process. It includes one filter heater for maintaining appropriate temperature range i.e.15 degrees to 32 degrees Celsius for cell culture expansion.

Get Customization of Full [emailprotected] https://www.absolutemarketsinsights.com/request_for_customization.php?id=102

Contact Us:

Company: Absolute Markets InsightsEmail Id:[emailprotected]Phone: +91-740-024-2424Contact Name: Shreyas TannaWebsite:www.absolutemarketsinsights.com/

Follow Us on Social Media:

https://www.facebook.com/AbsoluteMarketsInsights/https://twitter.com/AbsoluteMIhttps://www.linkedin.com/company/absolute-markets-insights/https://plus.google.com/117657938830005040584

Excerpt from:

Find Out Why Bioreactor Market is thriving worldwide by top key players like mergency Response USA, Buddi US, LLC, Connect America - Owned

BCLI: Phase 3 ALS Data Expected by the End of November 2020 – Zacks Small Cap Research

Posted on by

By David Bautz, PhD

NASDAQ:BCLI

READ THE FULL BCLI RESEARCH REPORT

Business Update

Topline Data from Phase 3 ALS Trial Before End of November 2020

BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn in patients with amyotrophic lateral sclerosis (ALS) (NCT03280056). A total of 200 patients were randomized 1:1 to receive NurOwn or placebo in the randomized, double blind, placebo controlled, multi-dose trial. Cells were extracted once from each patient prior to treatment, with all administrations of NurOwn derived from the same extraction of cells due to a cryopreservation process the company developed for long-term storage of mesenchymal stem cells (MSC). Just as with the companys prior studies, there was a 3-month run-in period prior to the first treatment with two additional NurOwn treatments occurring two and four months following the first treatment. The company is focusing the trial on faster-progressing ALS patients since those patients demonstrated superior outcomes in the Phase 2 trial of NurOwn. The primary outcome of the trial is the ALSFRS-R score responder analysis and we now anticipate topline results before the end of November 2020.

Update on Phase 2 Progressive Multiple Sclerosis Trial

BrainStorm is currently conducting a Phase 2 clinical trial of NurOwn in patients with progressive multiple sclerosis (MS) (NCT03799718). The trial is an open label, single arm study that is enrolling patients with progressive MS with Expanded Disability Status Scale (EDSS) scores of 3.0 6.5. The primary endpoint of the study is the safety and tolerability of three doses of NurOwn with secondary endpoints examining the timed 25-foot walking speed or 9-hole peg test (both validated MS clinical outcome assessments) along with paired cerebrospinal fluid (CSF) and blood biomarker analysis. The National Multiple Sclerosis Society awarded the company a $0.5 million grant to help fund the study.

The trial is now fully enrolled and we anticipate dosing to be completed for all patients by the end of 2020. While the company had previously considered performing an interim analysis, since topline data would be available soon after an interim analysis could be performed the company has decided against performing an interim analysis and will instead report topline data for all 20 patients when it becomes available.

NurOwn Derived Exosomes Show Promise in Preclinical ARDS Study

On July 23, 2020, BrainStorm announced the successful completion of the first milestone in developing an exosome-based platform for the treatment of severe acute respiratory distress syndrome (ARDS) caused by COVID-19. Exosomes are small vesicles (30-150 nm) that are secreted by all cell types. Exosomes from mesenchymal stem cells (MSCs), from which NurOwn is derived, can penetrate into deep tissues and deliver various bioactive molecules. In addition, they can be delivered both intravenously or intratracheally.

BrainStorm conducted a preclinical study of MSC-derived exosomes in a mouse model of lipopolysaccharide (LPS)-induced ARDS. Treatment with intratracheally administered exosomes resulted in a statistically significant improvement in various lung functions, including functional lung recovery and decreased lung damage, as judged by the lung disease severity score (P=0.03). In addition, they led to a reduction in a number of pro-inflammatory cytokines. Lastly, exosomes derived from MSC-NTF cells were superior to exosomes derived from nave MSC from the same donor.

We anticipate the results being submitted to a peer reviewed journal for publication and the company is currently deciding whether to initiate a clinical trial program in COVID-19 patients with ARDS.

Financial Update

On August 5, 2020, BrainStorm announced financial results for the second quarter of 2020. As anticipated, the company did not report any revenues during the second quarter of 2020. Net R&D expenses for the second quarter of 2020 were $5.7 million, compared to $3.6 million for the second quarter of 2019. The increase was primarily due to an increase in payroll and stock-based compensation and a decrease in support from the Israel Innovation Authority (IIA) and California Institute for Regenerative Medicine (CIRM) along with a decrease in costs related to the Phase 3 and Phase 2 clinical trials. Excluding participation from the IIA and CIRM, R&D expenses were $6.0 million in the second quarter of 2020, compared to $6.5 million in the second quarter of 2019. G&A expenses for the second quarter of 2020 were $1.7 million, compared to $1.3 million in the second quarter of 2019. The increase was primarily due to increased payroll and stock-based compensation.

The company exited the second quarter of 2020 with approximately $16.2 million in cash, cash equivalents, and short-term investments. Subsequent to the end of the quarter, the company raised gross proceeds of approximately $13.7 million from the $50 million ATM facility entered into in March 2020 through the sale of 945,082 shares at an average price of $14.48 per share. In addition, the company raised gross proceeds of approximately $6.3 million from the exercise of warrants. We estimate that the company currently has approximately $35 million in cash, cash equivalents, and short-term investments.

As of July 31, 2020, the company had approximately 31.5 million shares outstanding and, when factoring in warrants and stock options, a fully diluted share count of approximately 37.0 million.

Conclusion

The countdown is on to the topline data release for the Phase 3 ALS trial, with those results expected before the end of November 2020. Even with the great run the stock has had since its recent lows in March 2020, we continue to view the shares as undervalued as we currently forecast peak sales for NurOwn of >$1 billion in ALS, >$500 million in MS, and >$2 billion in Alzheimers disease. We recently made a slight change to our model, in which we decreased the discount rate from 17% to 13%, and combined with the recent financing activity has resulted in an increase to our valuation to $33 per share.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.

Go here to read the rest:

BCLI: Phase 3 ALS Data Expected by the End of November 2020 - Zacks Small Cap Research

How Attacks on Faith, Family, and Conscience Threaten All Our Freedoms – Daily Signal

Posted on by

During these tumultuous times, as practically every American institution comes under attack from the far left and its allies, two of our most essential values seem to be especially targeted in an effort to transform America.

Those values are faith and family, the two essential pillars that serve as true stabilizing factors in any society.

The attacks on faith and family seem to be relentless.

In Nevada, amid the COVID-19 crisis, casinos are open, but churches are told they must remain closed. In California, Gov. Gavin Newsom told churches that their congregants no longer could sing worship songs, even though they are wearing protective masks while doing so. In Portland, Oregon, radicals not only are burning the flag but Bibles as well. And tragically, in the same vein, vandals are targeting churches.

Want to watch more videos from The Daily Signal? Subscribe to our YouTube channel! Just go here: https://www.youtube.com/dailysignal

So, how did we get to this point? It didnt happen overnight.

It is not a coincidence that our current cultural condition, and the turn to hard-left progressivism, began in the late 1950s and into the 1960s, as these values started to erode and lose influence in American society.

Those on the far left actively were launching attackssometimes stealthilythrough seizing all the major corridors of cultural and political influence.

When these pillars of faith and familyboth of which are key components of the Judeo-Christian principles upon which our nation was foundedstarted to come under attack, all other principles such as fiscal restraint, freedom of conscience, and limited government came under assault as well.

Regarding the family, several factors led our nation down the progressive path and away from conservatism. The social engineering of President Lyndon Johnsons liberal Great Society of the mid-1960s devastated the family, as fathers no longer had to accept fiscal responsibility for the children they bore.

Legalized abortion greatly devalued human life and further enabled personal irresponsibility and selfish, rather than selfless, behavior. No-fault divorce made it easy for either spouse to walk away from the commitment of until death do us part, leaving a trail of broken children behind.

And attacks on the fundamental beliefs of the faithful created a culture where those beliefs not only were mocked but increasingly criminalized. One example: the persecution of those who do not wish to use their skills to participate in facilitating abortions.

On the faith front, many mainline denominations swapped out the Gospel for social justice and the abandonment of absolute truth. This left a spiritual vacuum for progressive thoughtwhich sought governmental, rather than faith-based, solutionsto fill. Lost were the virtues of prudence, justice, fortitude, and temperanceall of which are needed for society to thrive.

Thus, once the pillars of faith and the family were weakened, the rest of the house started to collapse, just as Abraham Lincoln warned the nation in 1858 that a house divided against itself cannot stand.

With the gap that was left by the removal of these two pillars of faith and family, progressives were able to introduce policies that destabilized rather than stabilized society. One such policy: encouraging single parenting, which has led to the tragic loss of fathersan essential individual in every childs lifein ever-increasing numbers.

Progressives attacked religious freedom and the role churches play in creating a safety net that government never couldby feeding both the body and the soul.

Much of the current out-of-control government spending is tied to government takeover and destruction of both these institutions, which taught self-reliance and personal responsibility.

We wrote at length about this in our book American Restoration: How Faith, Family, and Personal Sacrifice Can Heal Our Nation, which provides a conservative, faith-based response to our nations various ailments.

The breakdown of the family has been a primary factor in the societal chaos we are experiencing. It has led to massive government spending that enables the very behaviors that continue a cycle of despair and destabilization.

The decreased role of faith has led to the breakdown of community, neighbors helping neighbors, and the other societal supports that government cannot recreate but tries toagain through more massive spending, which only perpetuates problems instead of solving them.

The disregard forand eventual mocking ofreligious faith and the values of selflessness and personal responsibility it instills have led to a nation that values its privileges over its principles.

And the result of that, as President Dwight Eisenhower warned us in his 1953 inaugural address, is that a nation soon loses both.

Why? Because both family and faith go to the essence of what makes a healthy society. A functional, healthy family provides for and equips the next generation to be self-reliant citizens, not dependent upon government programs for their sustenance. It provides the next generation with the tools and the confidence to succeed in life.

In addition, a young boy who grows up with a strong father as a role modela father who leads by example of how to love his wife, shepherd his children, and make sacrifices that benefit bothlikely will follow in his fathers footsteps. A young boy without that model will try to figure it out on his ownoften with disastrous results.

In the same way, a young girl who knows what it is to be valued and loved by a man will make good decisions regarding future relationships. Those good decisions will result in less need for government intrusion and taxpayer support.

In many ways, the church does this as well. It provides a moral framework that teaches that all people are worthy of dignity and respect as they have been created Imago Deiin the image of God.

For the principles of limited government and a republican government to succeed, morality must be part of the equation. John Adams, signer of the Declaration of Independence and the second president of the United States, recognized this fact when he wrote to the Massachusetts Militia in 1798: Our Constitution was made only for a moral and religious People. It is wholly inadequate to the government of any other.

Or as Benjamin Franklin wrote: Only a virtuous people are capable of freedom. As nations become corrupt and vicious, they have more need of masters.

Progressivism is a master that restricts freedom; conservatism seeks to expand freedom, which can be expanded only if a society is virtuous.

Thus, with a moral framework in place, people are more self-reliant, more likely to make healthy decisions that benefit society rather than poor ones that result in dependence on government. With healthy families, children will thrive and make positive contributions to society. With a strong faith, and the virtues it instills, society will flourish.

And, sadly, when those values are attacked and weakened, society suffers and descends into personal and corporate chaos. The result is the antithesis of what the left professes it seeks to advance, which is unity (on its terms) and progress. Instead, all we are left with is the bitter fruit of division and descension into cultural darkness.

The battle to overcome this darkness is daunting, but it can be won if we stand up to these attacks on faith, family, and conscience rather than slink away in retreat. As our Founding Fathers wrote, only a moral, righteous, and virtuous people can be free.

If future generations are going to enjoy the freedoms we have cherished, we must return to the moral framework that made these freedoms possible in the first place. Once that moral foundation is rebuilt, Americas house once again can stand strong, united against any storm it may face.

Read the original post:

How Attacks on Faith, Family, and Conscience Threaten All Our Freedoms - Daily Signal

Gaucher Disease Treatment Market Size, Top Companies, Trends, Growth Factors Details by Regions, Types and Applications – Owned

Posted on by

The global Gaucher Disease Treatment Market is estimated to reach $2.11 Billion By 2025 and is projected to grow at a CAGR of 2.8% during the forecast period according to a new study published by Polaris Market Research.

The report offers a deep-dive analysis on global market insights, market trends, key driving factors along with the challenges. The report also focuses on different segments and outlines the growth prospects across all the geographies covering major countries. The study outlines the major competitive scenarios of the key players operating in the market along with their strategic initiatives, and recent developments such as new products or services introductions along with the mergers and acquisitions and R&D activities. The study also focuses on the traction these major players are generating in different regional pockets across major countries.

The sample for the study can be requested using the following link: https://www.polarismarketresearch.com/industry-analysis/gaucher-disease-treatment-market/request-for-sample

The analysis on different segments of the Gaucher Disease Treatment Market provided in the report would help to gain insights about current market scenarios and future market trends. All these segments are further bifurcated by regions and countries, thus making it possible for the decision makers to understand the market situation. Major regions included in the report include North America, Europe, Asia Pacific, Latin America and Middle East & the African region.

The worldwide Gaucher Disease Treatment Market study includes premium industry insights such as ecosystem analysis, value chain analysis, and competitive ranking/competitors market share analysis which would help key decision makers, stakeholders, and industry analysts to make cost-effective and efficient decisions.

Special discount can be availed for this study @ https://www.polarismarketresearch.com/industry-analysis/gaucher-disease-treatment-market/request-for-discount-pricing

Some of the major players profiled in the Gaucher Disease Treatment Market study include:

Sonafi (Genzyme Corporation), Pfizer Inc., Acetelion Pharmaceutical (J&J Ltd.), Shire Human Genetics Therapies, Inc., Erad Therapeutic Inc., and JCR Pharmaceuticals Co Ltd.

Polaris Market research has segmented the Gaucher Disease Treatment Market report on the basis disease type, and treatment type and region

Gaucher Disease Treatment Market Size and Forecast by Disease type, 2018 2025

Gaucher Disease Treatment Market Size and Forecast by Treatment type, 2018 2025

Glucaric acid Market Size and Forecast, 2017-2026 by Region

What to expect from this research study

To customize the study according to your specific requirements please click @ https://www.polarismarketresearch.com/industry-analysis/gaucher-disease-treatment-market/request-for-customization

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us-

Polaris Market Research

Phone: 1-646-568-9980

Email:[emailprotected]

Web:www.polarismarketresearch.com

Follow us-LinkedIn|Twitter|Facebook

Read this article:

Gaucher Disease Treatment Market Size, Top Companies, Trends, Growth Factors Details by Regions, Types and Applications - Owned

LUMINEX : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) – marketscreener.com

Posted on by

The following information should be read in conjunction with the condensedconsolidated financial statements and the accompanying notes included in Part I,Item 1 of this Quarterly Report on Form 10-Q, and the "Risk Factors" included inPart I, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March31, 2020, and as updated by Part II, Item 1A of our 2019 10-K, as updated byPart II, Item 1A of this Quarterly Report on Form 10-Q.

SAFE HARBOR CAUTIONARY STATEMENT

risks and uncertainties relating to market demand and acceptance of ourproducts and technology, including ARIES, MultiCode, xMAP, xMAP INTELLIFLEX,VERIGENE, VERIGENE II, Guava, Muse, Amnis, and NxTAG products;

timing of and process for regulatory approvals;

our ability to scale manufacturing operations (particularly with respect to ourproducts that recently received U.S. Food and Drug Administration (FDA)Emergency Use Authorization (EUA) clearance) and manage operating expenses,gross margins and inventory levels;

potential shortages, or increases in costs, of components or other disruptionsto our manufacturing operations;

our ability to obtain and enforce intellectual property protections on ourproducts and technologies;

our ability to successfully develop and launch new products in a timely manner;

competition and competitive technologies utilized by our competitors;

dependence on strategic partners for development, commercialization anddistribution of products;

reliance upon the accuracy and completeness of the information received fromstrategic partners to determine the appropriate financial reporting;

risks and uncertainties associated with implementing our acquisition strategy,and our challenge to identify acquisition targets, including our ability toobtain financing on acceptable terms;

our ability to integrate acquired companies or selected assets into ourconsolidated business operations, and the ability to fully realize the benefitsof our acquisitions;

our ability to comply with applicable laws, regulations, policies andprocedures;

changes in principal members of our management staff;

our increasing dependency on information technology to enable us to improve theeffectiveness of our operations and to monitor financial accuracy andefficiency;

implementation, including any modification, of our strategic operating plans;

uncertainty regarding the outcome or expense of any litigation brought againstor initiated by us;

--------------------------------------------------------------------------------

Table of Contents

reliance on third party distributors for distribution of specificLuminex-developed and manufactured assay products; and

risks related to the issuance of the Notes and with respect to the ConvertibleNote Hedge Transactions.

OVERVIEW

Flexibility/scalability

Both protein and nucleic acid applications on a single platform

High throughput

Ease of use

Most xMAP-based assays are simple to perform. A test sample is added to asolution containing microspheres that have been coated with reagents. Thesolution is then processed through one of our xMAP Systems, which incorporateproprietary software to automate data acquisition and analysis in real-time.

Cost-effective

Our Amnis/Guava Technologies

Our Non-Automated Technologies

We have multiple assay development activities ongoing and these activities arefocused in the areas of infectious disease, human genetics and pharmacogenomics.

Our ARIES Technology

Our Market Approach

Second Quarter 2020 Highlights

Record revenue, profitability and cash flow generation in the quarterended June 30, 2020.

Consolidated revenue was $109.5 million for the quarter ended June 30, 2020, a32% increase over the prior year period.

Total assay revenue increased to $61.2 million for the quarter ended June 30,2020, a 95% increase over the prior year period.

Sample-to-answer assay revenue increased to $25.8 million for the quarterended June 30, 2020, a 56% increase over the prior year period.

Profitability increased to $12.5 million for the quarter ended June 30, 2020,an increase of more than 350% vs. the prior year period.

Issued $260.0 million principal amount of Notes due in May 2025.

Cash generation of approximately $31.0 million for the quarter ended June 30,2020, before the net proceeds of $217.6 million from the issuance of the Notes.

Received FDA EUA for the ARIES SARS-CoV-2 Assay on April 6, 2020.

Submitted EUA request to the FDA for the xMAP SARS-CoV-2 Multi-Antigen IgGAssay on June 29, 2020, which was subsequently issued on July 16, 2020.

COVID-19 Considerations

BARDA Contracts

Consumables Sales and Royalty Revenue Trends

Growth in Inventory

We expect our areas of focus over the next twelve months to be:

delivering on our revenue growth goals;

accelerating development and commercialization of the assays on oursample-to-answer diagnostic systems;

--------------------------------------------------------------------------------

Table of Contentscompleting development and commercialization of the next generationsample-to-answer system, VERIGENE II, our next generation xMAP System, xMAPINTELLIFLEX, and our next generation Guava instrument, Guava Next Gen;

improvement of ARIES and VERIGENE gross margins;

placements of our VERIGENE and ARIES Systems, our sample-to-answer platformsand assays;

increasing the growth of our LTG revenue through enrichment of our existingpartner relationships and the addition of new partners;

maintenance and improvement of our existing products and the timelydevelopment, completion and successful commercial launch of our pipelineproducts;

adoption and use of our platforms and consumables by our customers for theirtesting services; and

expansion and enhancement of our installed base of systems and our marketposition within our identified target market segments.

KEY PERFORMANCE INDICATORS

--------------------------------------------------------------------------------

Table of ContentsRevenues, disaggregated by revenue source, into the following primarycategories:

The Company's ability to meet anticipated product development timelines and todeliver on our planned commercial product launches.

--------------------------------------------------------------------------------

Table of Contents

RESULTS OF OPERATIONS

THREE MONTHS ENDED JUNE 30, 2020 COMPARED TO THREE MONTHS ENDED JUNE 30, 2019

The following table presents our revenues disaggregated by revenue source forthe three months ended June 30, 2020 and 2019 as follows:

SIX MONTHS ENDED JUNE 30, 2020 COMPARED TO SIX MONTHS ENDED JUNE 30, 2019

--------------------------------------------------------------------------------

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

Link:

LUMINEX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com

Psoriasis: Types, Pictures, Causes, Symptoms, Treatments …

Posted on by

Alwan, W., and F.O. Nestle. "Pathogenesis and Treatment of Psoriasis: Exploiting Pathophysiological Pathways for Precision Medicine." Clin Exp Rheumatol 33 (Suppl. 93): S2-S6.

Arndt, Kenneth A., eds., et al. "Topical Therapies for Psoriasis." Seminars in Cutaneous Medicine and Surgery 35.2S Mar. 2016: S35-S46.

Benhadou, Fairda, Dillon Mintoff, and Vronique del Marmol. "Psoriasis: Keratinocytes or Immune Cells -- Which Is the Trigger?" Dermatology Dec. 19, 2018.

Conrad, Curdin, Michel Gilliet. "Psoriasis: From Pathogenesis to Targeted Therapies." Clinical Reviews in Allergy & Immunology Jan. 18, 2015.

Dowlatshahi, E.A., E.A.M van der Voort, L.R. Arends, and T. Nijsten. "Markers of Systemic Inflammation in Psoriasis: A Systematic Review and Meta-Analysis." British Journal of Dermatology 169.2 Aug. 2013: 266-282.

Georgescu, Simona-Roxana, et al. "Advances in Understanding the Immunological Pathways in Psoriasis." International Journal of Molecular Sciences 20.739 Feb. 10, 2019: 2-17.

Greb, Jacqueline E., et al. "Psoriasis." Nature Reviews Disease Primers 2 (2016): 1-17.

Kaushik, Shivani B., and Mark G. Lebwohl. "Review of Safety and Efficacy of Approved Systemic Psoriasis Therapies." International Journal of Dermatology 2018.

National Psoriasis Foundation. "Systemic Treatments: Biologics and Oral Treatments." 1-25.

Ogawa, Eisaku, Yuki Sato, Akane Minagawa, and Ryuhei Okuyama. "Pathogenesis of Psoriasis and Development of Treatment." The Journal of Dermatology 2017: 1-9.

Stiff, Katherine M., Katelyn R. Glines, Caroline L. Porter, Abigail Cline & StevenR. Feldman. "Current pharmacological treatment guidelines for psoriasis and psoriaticarthritis." Expert Review of Clinical Pharmacology (2018).

Villaseor-Park, Jennifer, David Wheeler, and Lisa Grandinetti. "Psoriasis: Evolving Treatment for a Complex Disease." Cleveland Clinic Journal of Medicine 79.6 June 2012: 413-423.

Woo, Yu Ri, Dae Ho Cho, and Hyun Jeong Park. "Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis." International Journal of Molecular Sciences 18 Dec. 11, 2017: 1-26.

Read this article:

Psoriasis: Types, Pictures, Causes, Symptoms, Treatments ...

At least 26 migrants land on Kent beaches – BBC News

Posted on by

Image caption One boat carrying 14 migrants landed at Kingsdown on Saturday morning

At least two boats carrying a total of 26 migrants have arrived on the Kent coast after crossing the English Channel.

One boat reportedly carrying 12 migrants, was picked up by Border Force patrols at about 10:00 BST and brought to shore at Dover.

A second boat carrying 14 migrants landed at Kingsdown shortly after.

It is understood there were also landings at Deal and Folkestone although they have not been confirmed.

The Coastguard confirmed it was dealing with "a number" of incidents.

The Home Office has been contacted for a comment.

It was announced earlier the Home Office has sent a formal request to defence chiefs asking for help to deal with migrants attempting to cross the English Channel.

The Home Office said it was possible the Royal Navy could be brought in to patrol the migrant traffic.

Dover and Deal MP Natalie Elphicke said: "We've gone into this record number of people crossing over this year all options need to be on the table."

On Friday a record number of unaccompanied migrant children arrived in the UK.

The 23 youths were taken into the care of Kent County Council, on top of the 70 who arrived in July.

Those figures do not include those travelling with their families, and the Home Office has refused to confirm the number of children arriving.

Since January 2019 at least 5,800 people have entered the UK on small boats, and about 155 have been returned to Europe.

The Home Office blamed current regulations - which determine where an asylum-seeker's claim is heard - for the comparatively low number of people to have been returned to Europe.

On Friday Home Secretary Priti Patel said the boats needed to be prevented from leaving France.

On Thursday a record number of 235 people made the crossing in 17 vessels on Thursday.

Follow BBC South East on Facebook, on Twitter, and on Instagram. Send your story ideas to southeasttoday@bbc.co.uk.

Read the original post:

At least 26 migrants land on Kent beaches - BBC News

Galveston must keep its word on sudden beach closures – Galveston County Daily News

Posted on by

Were willing to take Mayor pro tem Craig Browns word that city leaders have no plans to close the beaches during Labor Day weekend, as they did with very short notice just before the long Fourth of July holiday.

Its understandable, however, that some in Galveston, especially in the business community, are skeptical and worried about a repeat of that last-minute July decision, which delivered a substantial financial blow to many attempting to stay afloat during the COVID-19 pandemic.

Once bitten, and all that.

Part of the problem is city leaders cant or wont talk in any detail or with any assurance about what might make them close the beaches again. Thats not unique to them; its a problem with the whole pandemic management program at every level.

The thing that will call the tune and decide our fates is a nebulous, pulsating cloud of mostly unnamed, much less defined, data points. Its somewhat akin to being back in the hands of the oracles and at the mercy of signs and portents.

We all must suck it up and drive on, but for how long and to where exactly; who knows?

No matter whether that was inevitable or because of some avoidable systemic failure, it has inevitably caused people to doubt and divide into camps of believers and non-believers. In fact, the story of COVID-19 every day reads more like a tale of religious schism.

Be that as it may, its not on the heads of local leaders.

The uncertainty Galveston leaders have expressed about managing tourism during this pandemic is the most understandable and forgivable.

The city council is made up of volunteers with no special expertise in epidemiology, or necessarily business, for that matter, attempting to navigate their own professional and personal lives through an environment well beyond their control.

Theyre in the same boat as the rest of us, except theyre caught between constituencies whose agendas and recommendations, or demands, are both valid in context and exactly opposite in effect open, close, now, later, do, dont.

One decision might kill people, the other kill businesses and jobs.

Its hard to find a spot to build compromise in a landscape of such diametric absolutes.

We have to give leaders, especially the local volunteers, some room to err on the side of caution.

What we reasonably can expect even from them, however, is refrain from dropping anything heavy on our heads just out of the blue, as Galveston leaders did before the Fourth of July Beach closures.

This is not just a question of inconvenience. Businesses such as those accepting reservations must be able to communicate with customers or face their wrath.

It was wrong for the city of Galveston to have allowed hotels and beach rental operators, to name a couple, to continue booking rooms without even an honest heads-up that closing the beaches was under serious discussion.

Whatever else it does, the city cant do that again.

More broadly, the keepers of the data points should consider maybe cooking them down to something digestible.

If its too soon to reopen schools, just for example, whats the basis of that argument and what should we look for to change?

A few benchmarks would, if nothing else, give us something to root for.

Michael A. Smith

Read the original post:

Galveston must keep its word on sudden beach closures - Galveston County Daily News

10 of the UK’s best seaside cafes and beach shacks – The Guardian

Posted on by

Fresh From The Sea, Port Isaac, Cornwall

Port Isaac has a medieval harbour, which once handled coal and pottery. Now, tourists come to walk the coastal path and visit the neighbouring harbour of Port Gaverne and its rock pools. Fisherman Calum Greenhalgh can often be seen hauling his catch up the hill in Port Isaac, and it is his fish shop and cafe, run with his wife Tracey, that Cornish chef Nathan Outlaw recommends: He catches the crabs and lobsters in the bay and she cooks and serves them. They do the best crab sandwich (9.75) in the world! freshfromthesea.co.uk

Less than 90 minutes by train from London St Pancras lies Broadstairs, with its fishermens cottages and retro ice-cream parlour, Morellis, complete with soda fountain and jukebox. Guardian food writer Felicity Cloake has found a new reason to visit: Flotsam and Jetsam, a pop-up from seafront restaurant Wyatt and Jones, which offers a dizzying array of sauces such as squid ink hot sauce and oyster mayo which are perfect squeezed on to a cone of frites (3.50), as well as crispy crab dumplings (6.50). On Facebook

Going to the village and fishing port of Saint Monans is like a trip back in time, with its 14th-century foreshore church, 17th-century houses nudging the harbourside and salt pans from its industrial past. Its also on the 117-mile Fife Coastal Path (linking the Firth of Forth with the Firth of Tay). Scott Smith, chef and co-owner of Edinburghs Fhior, suggests stopping for lunch: Although its a smokehouse, I always go for the fresh lobster. Half a lobster with tarragon mayonnaise is 14.50. eastpier.co.uk

Fossil hunting on the beaches between Charmouth and Lyme Regis is a fun way to explore Dorsets Jurassic Coast. Food writer and chef Gill Meller knows the region and this cafe is his top tip: Famous for its vegan shakshuka, it opens early so you can have a coffee after a swim, sit outside and look out over the Cobb and the bay. Its unpretentious, inexpensive and where youll find the fishermen. 24 Marine Parade, no website

The Magpie was built in 1750 as a merchants house and overlooks Whitby harbour and is food writer Yasmin Khans favourite: Its an atmospheric place. It has the best fish and chips in the UK, with chips fried in beef dripping. Its also where author Bram Stoker got inspiration for Dracula. (In 1890, Stoker arrived at Mrs Veazeys guesthouse in the town.) The huge menu includes cod and chips (11.50) and Whitby wholetail scampi with chips (12.50). magpiecafe.co.uk

This Devon town is harbourside perfection on a sunny day. A wander to Churston Cove is a good way to start, as is a visit to Berry Head national nature reserve to see the breeding colonies of guillemots. Seafood ambassador and chef Mitch Tonks says there is no need to stray far for lunch. Overlooking the bay, Shoals is part of a salt-water lido. Run by fish merchant Sean Perkes and his wife Sarah, its all about fresh local fish. The skate wing is fabulous. The catch of the day, served with sides, is 13.95. shoalsbrixham.co.uk

Think Dungeness, think shingle beaches, Derek Jarmans garden and the looming nuclear power station on the headland. The local beer is good, too, so visit the tap room at Wantsum Brewery. Food writer Kate Young describes the Snack Shack as a small shipping container featuring a kitchen, surrounded by a collection of weathered wooden picnic tables. Ive thought about the fish baps (on soft rolls, with fresh salad, served with rough chunky chips) at least once a week since I visited. Its tiny, and tentatively open, so steer clear at weekends and peak hours to avoid overcrowding. dungenesssnackshack.net

Anglesey is perfect for paddling, especially Church Bay with its cliff paths and rock pools, or for windsurfing at Trearddur Bay. Food writer and blogger Karen Burns-Booth suggests refuelling in the unlikely setting of a tin shed on a campsite. The Marram Grass is a favourite. It started off serving campers and now does creative but unpretentious restaurant-quality dishes at the seaside. Anglesey crab and lemon tatws rosti is 9, Menai mussels with tarragon basil 10. themarramgrass.com

For Nicola Miller, food writer and columnist, a day well-spent at the Suffolk port town would be an early lunch at Winkles At The Ferry (scampi and chips, 9.95) then a walk along the Deben to where it meets the sea. Follow the coastal path through to Felixstowe proper with its sandy beaches, pier and arcade then to Landguard Fort, near the Port of Felixstowe, which has a nature reserve, empty shingle-and-sand beaches and a wonderful view of the shipping channels. On Facebook

Ballycastle, with its seafront gardens, sandy beach and salt-weathered Pans Rocks, is a beauty: ferries also run to Rathlin Island for seal-spotting. Northern Irish food writer Diana Henry says: My brothers (and me, when Im in town) go to Mortons in the harbour. I take a bottle of champagne to the beach to have with the fish and chips, and my own mayo or tartare sauce, too. The cod supper is 8.10. On Facebook

See the article here:

10 of the UK's best seaside cafes and beach shacks - The Guardian

17-year-old girl airlifted with life-threatening injuries following crash on North Landing Bridge in Virginia Beach – WAVY.com

Posted on by

VIRGINIA BEACH, Va. (WAVY) A 17-year-old girl was airlifted to the hospital after suffering life-threatening injuries during a crash Friday night in Virginia Beach.

The call reporting the incident came in around 10:25 p.m. Friday in the 3900 block of North Landing Road.

Initial investigation say an SUV was traveling northbound on North Landing Road from Chesapeake into Virginia Beach at a high rate of speed.

After the vehicle crossed the North Landing Bridge, it went off the road and struck a pole and several objects, which caused it to overturn.

The driver, a 17-year-old boy sustained non life-threatening injuries and was sent to the hospital.

His passenger, however, a 17-year-old girl, suffered life-threatening injuries and was airlifted by first responders.

North Landing Bridge was shut down for several hours in both directions following the single-vehicle accident, but reopened just after 9 a.m. Saturday.

Police have not release additional details.

Stay with WAVY.com for details.

Read more from the original source:

17-year-old girl airlifted with life-threatening injuries following crash on North Landing Bridge in Virginia Beach - WAVY.com

Cloud Radio Access Network Market Research Report by Technology, by Component, by Network, by Deployment Area – Global Forecast to 2025 – Cumulative…

Posted on by

New York, Aug. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cloud Radio Access Network Market Research Report by Technology, by Component, by Network, by Deployment Area - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913866/?utm_source=GNW

The Global Cloud Radio Access Network Market is expected to grow from USD 718.96 Million in 2019 to USD 1,353.96 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.12%.

Market Segmentation & Coverage:This research report categorizes the Cloud Radio Access Network to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Technology, the Cloud Radio Access Network Market studied across Centralization Technology and Virtualization Technology. The Centralization Technology further studied across Layer-2 Cloud Radio Access Network and Layer-3 Cloud Radio Access Network. The Virtualization Technology further studied across Architecture of Virtualization Technology and Flexran.

Based on Component, the Cloud Radio Access Network Market studied across Services and Solution. The Services further studied across Consulting, Maintenance & Support, Planning & Implementation, and Training. The Solution further studied across Cloud Public Radio Interface - Radio Frequency Analyzer, Cloud-Based Test Management Tool, and Optical Time Domain Reflectometer Technology-Based Testing Module.

Based on Network, the Cloud Radio Access Network Market studied across 3G, 4G, and 5G.

Based on Deployment Area, the Cloud Radio Access Network Market studied across High-Density Urban Areas, Large Public Venues, Suburban & Rural Areas, and Targeted Outdoor Urban Areas.

Based on Geography, the Cloud Radio Access Network Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cloud Radio Access Network Market including Altiostar, Asocs Ltd., Cisco Systems, Inc., Ericsson AB, Fujitsu, Huawei Technologies Co., Ltd., Intel Corporation, Mavenir Systems, NEC Corporation, Nokia Corporation, Samsung Electronics Co Ltd, and ZTE Corporation.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cloud Radio Access Network Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Cloud Radio Access Network Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cloud Radio Access Network Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cloud Radio Access Network Market?4. What is the competitive strategic window for opportunities in the Global Cloud Radio Access Network Market?5. What are the technology trends and regulatory frameworks in the Global Cloud Radio Access Network Market?6. What are the modes and strategic moves considered suitable for entering the Global Cloud Radio Access Network Market?Read the full report: https://www.reportlinker.com/p05913866/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

View post:

Cloud Radio Access Network Market Research Report by Technology, by Component, by Network, by Deployment Area - Global Forecast to 2025 - Cumulative...

The Intersection of Technology And Patient Privacy In The COVID-19 Landscape (And Beyond) – JD Supra

Posted on by

Employers in the healthcare industry are no strangers to change. After all, you are constantly adapting to cutting-edge medical technologies to improve and expand patient care, reform health inequities, advance care coordination and continuity, facilitate data analysis for diagnosis and treatment, and harmonize advanced levels of care across the country. Nonetheless, in hasty response to the pandemic, the industry is experiencing a profusion of advanced technologies now more than ever. These primarily include the unparalleled resurgence of telehealth as well as complex advancements to the nuanced roles of artificial intelligence, analytics, and biometrics to improve integrity of electronic health records (EHR), including migration to a cloud-based platform. In todays unpredictable and volatile COVID-19 environment, it is critical that you not only confront but embrace this advent of technology through continued employee education and training.

Of course, this is no easy task. In fact, the application of this technology to reality is wrought with challenges arising from providers legal duties and your moral imperative to safeguard patient privacy. It is incumbent for you to invest not only in the technologies themselves but in the continued education and training of employees to ensure patient privacy. Thus, it is also critical that you and your employees alike adhere to patient privacy laws, including HIPAA and other statutory obligations. To make matters all the more complicated, these obligations are currently changing, mirroring the volatility of the pandemics impact on the practice of medicine. Accordingly, this article seeks to educate healthcare employers as to the impact of these pioneering technologies on patient privacy laws and, despite the unpredictability of the current climate, forecast the staying power of telehealth and related evolving modalities.

Post-Pandemic Predictions For Telehealth Illustrate Need To Invest In The Technology

Given the current momentum of telehealth services, federal policymakers have enacted upwards of 30 changes to enable greater access to telehealth in the COVID-19 era. Driven by telehealths obvious unique ability to deliver contactless patient care, these changes include the relaxation of regulatory hurdles (specifically, the temporary lifting of penalties) by the Center for Medicare and Medicaid Services (CMS) and the Office of Civil Rights (OCR) around HIPAA.

In mid-March, the OCR announced easement of restrictions on telehealth during the pandemic, including the temporary lifting of penalties generally imposed on providers who use non-HIPAA compliant virtual communications technology during the public health emergency provided such use is in good faith. By way of vague guidance, the OCR announced that healthcare providers seeking to use telehealth to reach patients can use any non-public remote communication product that is available to communicate with patients. . . This exercise of discretion applies to telehealth provided for any reason, regardless of whether the telehealth service is related to the diagnosis and treatment of health conditions related to COVID-19.

In its announcement, the OCR specifically recognized the essential link telehealth affords patients and providers while removing the need to travel to burdened hospitals. OCR Director Roger Severino stated, We are empowering medical providers to serve patients wherever they are during this national public health emergency. . .We are especially concerned about reaching the most at risk, including older persons and persons with disabilities.

Unfortunately, the vague relaxation of many regulations by the Department of Health and Human Services (HHS) has left healthcare employers in the dark as to permanence. Concurrent with the introduction of a related bipartisan bill in mid-June and in response to the concerns of constituents largely made up of healthcare employers, senators from both sides of the aisle requested HHS and CMS provide a written plan for permanent changes to the rules around telehealth. The June 26 request specifically seeks guidance as to OCRs enforcement discretion of HIPAA compliance, including a security analysis of non-HIPAA compliant tools on which providers and patients rely during the current pandemic. While a formal response is outstanding, CMS Administrator Seema Verma acknowledged the importance of clarity for the future, stating that she cant imagine going back.

In response to the lack of guidance for healthcare constituents and in recognition of telehealths staying power, in early July, bipartisan legislation aimed at codifying clarity for telehealth regulations was introduced. Notably, the Exposure Notification Privacy Act would mandate that providers using telehealth services or other advanced modalities storing EHR to analyze patient data examples of which include patient data used in COVID-19 exposure notification systems obtain patient consent for specific utilization of said data.

The pending bills focus on preservation of patient privacy illuminates the significance of privacy. Echoing the publics concern, the American Medical Association recently released patient privacy principles warning that the government must not trade privacy for efficiency of telehealth. Accordingly, the importance of safeguarding patient privacy must remain at the forefront of healthcare employers minds when training employees on the provision of telehealth services as well as all tasks involving patient data stored in EHR.

Takeaways For Healthcare Employers

With the temporary relaxation of HIPAA penalties and other regulatory enforcement, providers have been afforded the unprecedented opportunity to offer telehealth without concern of major financial repercussions related to the technologys unique threat of exposure. In fact, many have touted the advent of telehealth amidst COVID as the unexpected experiment. Certainly, the value of telehealth services cannot be overstated and thus, the related investment in technology and employee training is pivotal.

However, with the hurried, en masse implementation of telehealth stemming from the pandemic, new challenges become evident. It is in this erratic environment that healthcare employers must function. To that end, as evidenced by public concern and thus forthcoming legislation, patient privacy and HIPAA compliance should remain of tantamount concern.

Ultimately, evidenced by telehealths vital role in evolving patient care, investment in the service is critical to continuing to operate as a provider in the 21st century. The question remains: to what degree? Nonetheless, from a legal preparedness and risk aversion standpoint, in continuing to utilize telehealth, healthcare employers should remain vigilant in the protection of patient privacy.

See original here:

The Intersection of Technology And Patient Privacy In The COVID-19 Landscape (And Beyond) - JD Supra

Global Bioremediation Technology & Services Market Outlook (2019 to 2027) – Featuring Ivey International, Probiosphere & Regenes Among Others…

Posted on by

DUBLIN--(BUSINESS WIRE)--The "Bioremediation Technology & Services - Global Market Outlook (2019 -2027)" report has been added to ResearchAndMarkets.com's offering.

The Global Bioremediation Technology & Services market accounted for $9.13 billion in 2019 and is expected to reach $17.53 billion by 2027 growing at a CAGR of 8.5% during the forecast period.

Some of the key factors propelling market growth are augment the usage of fungus for treatment process of soil, increase in oil trading and enlarge in oil-contaminated sites. However, treatment time is typically longer are the restraining factor for the growth of the market.

Bioremediation is the procedure, which uses organisms to neutralize or take away contamination from waste. This technique works by providing microorganisms with dissimilar materials such as fertilizers and oxygen as well as extra conditions to stay alive. The significance of bioremediation is that it does not use chemicals and permits the waste to be recycled once the contamination is removed or neutralized.

By product, in situ bioremediation segment is expected to grow at significant market share during the forecast period due to clean up hazardous compounds there in the surroundings. In suit bioremediation is used to neutralize pollutants together with hydrocarbons, chlorinated compounds, nitrates, and toxic metals among additional pollutants through a different of chemical mechanisms.

On the basis of geography, North America is anticipated to hold considerable market share during the forecast period due to an increase in the number of companies present bioremediation services in the region. Presence of chief manufacturing industries, and augment in government funding for research & development activities in the bioremediation field are driving market growth in the region.

Companies Mentioned

What the report offers:

Key Topics Covered:

1 Executive Summary

2 Preface

2.1 Abstract

2.2 Stake Holders

2.3 Research Scope

2.4 Research Methodology

2.4.1 Data Mining

2.4.2 Data Analysis

2.4.3 Data Validation

2.4.4 Research Approach

2.5 Research Sources

2.5.1 Primary Research Sources

2.5.2 Secondary Research Sources

2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Technology Analysis

3.7 Application Analysis

3.8 Emerging Markets

3.9 Impact of COVID-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Bioremediation Technology & Services Market, By Type

5.1 Introduction

5.2 Ex Situ Bioremediation

5.3 In Situ Bioremediation

6 Global Bioremediation Technology & Services Market, By Technology

6.1 Introduction

6.2 Phytoremediation

6.3 Bioaugmentation

6.4 Bioreactors

6.5 Land-based Treatments

6.6 Fungal Remediation

6.7 Biostimulation

7 Global Bioremediation Technology & Services Market, By Service

7.1 Introduction

7.2 Wastewater Remediation

7.3 Oilfield Remediation

7.4 Soil Remediation

8 Global Bioremediation Technology & Services Market, By Sales Channel

8.1 Introduction

8.2 Distributor

8.3 Direct Sales

9 Global Bioremediation Technology & Services Market, By Application

9.1 Introduction

9.2 Commercial

9.3 Residential

10 Global Bioremediation Technology & Services Market, By Geography

10.1 Introduction

10.2 North America

10.2.1 US

10.2.2 Canada

10.2.3 Mexico

10.3 Europe

10.3.1 Germany

10.3.2 UK

10.3.3 Italy

10.3.4 France

10.3.5 Spain

10.3.6 Rest of Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 New Zealand

10.4.6 South Korea

10.4.7 Rest of Asia Pacific

10.5 South America

10.5.1 Argentina

10.5.2 Brazil

10.5.3 Chile

10.5.4 Rest of South America

10.6 Middle East & Africa

10.6.1 Saudi Arabia

10.6.2 UAE

10.6.3 Qatar

10.6.4 South Africa

10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures

11.2 Acquisitions & Mergers

11.3 New Product Launch

Here is the original post:

Global Bioremediation Technology & Services Market Outlook (2019 to 2027) - Featuring Ivey International, Probiosphere & Regenes Among Others...

Global Mixed Reality Market (2020 to 2025) – by Technology, Display Devices, End-user, Application and Geography – ResearchAndMarkets.com – Business…

Posted on by

DUBLIN--(BUSINESS WIRE)--The "Mixed Reality Market - Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The Global Mixed Reality Market has recorded $1054.3 m in 2020 and it is estimated to surpass $9982.8 m by 2025 growing at an estimated rate of more than 73.2% during 2020 to 2025. Software and Hardware are witnessed as fast growing in the market with $718.5 and 336.5 million revenue with a CAGR of 69.1% and 81.4% respectively. Eye Glass Display Device holds $321.4 m in 2020 with 66.1% growth rate. Mixed Reality technology is going to uplift the market from infant phase to extreme extent.

Mixed reality symbolizes the controlled collision of the AR/VR and IoT trends. It is the merging of Real and Virtual worlds to develop new visualizations and environments in which both digital and physical objects and their data can co-exist and interact with each other. MR displays images on semi-transparent materials using a projector, then it will get reflected to the eye with the help of beam-splitting technology. MR is applied on various places like maintenance & operations, production, design & development, reporting & analytics, quality control and distribution.

This report incorporates an in-depth assessment of Mixed Reality Market by Technology, Display Devices, End-User, Application and Geography.

The various end-users assessed includes Maintenance, Defense, Archaeology & Tourism, Architecture & Construction, Interactive Product Content Management (IPCM), Simulation Based Learning (SBL), Navigation, Gaming and Entertainment, Medical and Education and Sports. Combination of augmented and virtual reality increases the productivity, accuracy and safety of maintenance. Much useful in military training and situational positions like in the battle field. Now-a-days populace are more engaged in gaming and entertainment which is soon going to boost the market in this sector.

The report incorporates in-depth assessment of the competitive landscape, product market sizing, product benchmarking, market trends, product developments, financial analysis, strategic analysis and so on to gauge the impact forces and potential opportunities of the market. Apart from this the report also includes a study of major developments in the market such as product launches, agreements, acquisitions, collaborations, mergers and so on to comprehend the prevailing market dynamics at present and its impact during the forecast period 2020-2025.

Key Takeaways from this Report

Key Topics Covered:

1. Mixed Reality Market Overview

2. Mixed Reality Market Executive Summary

3. Mixed Reality Market Landscape

3.1. Market Share Analysis

3.2. Comparative Analysis

4. Mixed Reality Market Forces

4.1. Market Drivers

4.2. Market Constraints

4.3. Market Challenges

4.4. Attractiveness of the Industry

5. Mixed Reality Market - Strategic Analysis

5.1. Value Chain Analysis

5.2. Opportunities Analysis

5.3. Product/Market Life Cycle Analysis

5.4. Suppliers and Distributors

6. Mixed Reality Market - By Technology

6.1. Hardware

6.2. Software and Algorithms

7. Mixed Reality Market - By Display Devices

7.1. Introduction

7.2. CAVE

7.3. Head-Up Display (HUD)

7.4. Head-Mounted Display

7.5. Personal Digital Assistant

7.6. Eyeglasses

8. Mixed Reality Market - By End-User

8.1. Introduction

8.2. Aerospace & Defense

8.3. Archaeology & Tourism

8.4. Architecture & Construction

8.5. Industrial & Manufacturing

8.6. Gaming and Entertainment

8.7. Medical

8.8. Government

8.9. Retail

8.10 Education

8.11 Sports

8.12. Others

9. Mixed Reality Market - By Application

9.1. Introduction

9.2. Maintenance

9.3. Military Training

9.4. Interactive Product Content Management (IPCM)

9.5. Simulation Based Learning (SBL)

9.6. Navigation

9.7. Others

10. Mixed Reality Market - By Geography

10.1. North America

10.2. South America

10.3. Europe

10.4. APAC

10.5. Middle East& Africa

11. Market Entropy

11.1. New Product Launches

11.2. M&As, Collaborations, JVs, Partnership

12. Company Profiles

12.1. Oculus VR LLC

12.2. Infinity Augmented Reality, Inc

12.3. Meta Company

12.4. Atheer, Inc

12.5. Vuzix Corporation

12.6. Canon, Inc

12.7. HTC Corporation

12.8. Daqri LLC.

12.9. Sulon Technologies Inc.

12.10. Lumus Ltd.

13. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/gwb9j0

Read the original here:

Global Mixed Reality Market (2020 to 2025) - by Technology, Display Devices, End-user, Application and Geography - ResearchAndMarkets.com - Business...